Sir David Attenborough 100th birthday tribute celebrating his contribution to nature documentaries and awareness of fungi and the natural world

Sir David Attenborough at 100: Inspiring Wonder in Nature and Fungi

Sir David Attenborough 100th birthday tribute celebrating his contribution to nature documentaries and awareness of fungi and the natural world

Celebrating 100 years of Sir David Attenborough and his extraordinary contribution to understanding nature, fungi and the living world.Today marks the 100th birthday of David Attenborough — a remarkable milestone for someone who has spent a lifetime helping the world see nature differently.

For many of us interested in fungi and aspergillosis, his work has also helped shine a light on a kingdom of life that was too often overlooked. Through documentaries exploring fungi, moulds, forests and hidden ecosystems, he helped bring the extraordinary world of fungi into homes around the globe — revealing not just beauty, but the vital role fungi play in life on Earth.

At a time when awareness of fungal disease and environmental mould exposure remains so important, that contribution matters greatly.

Happy 100th Birthday Sir David — and thank you for a century of curiosity, education and wonder.

Tribute from the BBC


Patient comparing blue reliever inhaler and combination AIR MART inhaler for asthma and aspergillosis

Blue inhalers, combination inhalers and aspergillosis: what patients need to know

Recent news about “blue inhalers” has caused understandable concern for people with asthma, ABPA and other aspergillosis-related lung conditions. The key message is: do not panic and do not stop any prescribed inhaler suddenly.

Blue reliever inhalers, such as salbutamol or Ventolin, remain important medicines and can be lifesaving during asthma symptoms or an asthma attack. However, asthma guidelines have changed because doctors now recognise that relying too heavily on a blue inhaler can be a sign that the underlying airway inflammation is not being well controlled.

What is a blue inhaler?

A blue inhaler usually contains a medicine called a short-acting beta2 agonist, often shortened to SABA. Salbutamol is the best-known example.

These inhalers work quickly by relaxing the muscles around the airways. This can relieve wheeze, chest tightness and breathlessness within minutes. However, a blue inhaler does not treat the airway inflammation that often drives asthma symptoms.

You can read more about reliever inhalers from Asthma + Lung UK.

Why are asthma guidelines changing?

Asthma is not just a condition of narrowed airways. It is also an inflammatory condition. A reliever inhaler may make breathing feel easier for a short time, but if inflammation is not treated, asthma may remain poorly controlled.

Frequent use of a blue reliever inhaler can therefore be a warning sign. It may mean that asthma treatment needs reviewing, especially if someone is needing their reliever often, waking at night, having flare-ups, or finding their normal activities limited.

The updated NICE/BTS/SIGN asthma guideline supports greater use of treatment plans that combine symptom relief with anti-inflammatory treatment.

What are AIR and MART inhalers?

Some patients are now prescribed a combination inhaler that contains:

  • a fast-acting reliever medicine to open the airways
  • an inhaled corticosteroid to reduce inflammation

These approaches are known as:

  • AIR – Anti-Inflammatory Reliever
  • MART – Maintenance and Reliever Therapy

With these plans, the combination inhaler may be used when symptoms occur. In MART, it is also used regularly every day as maintenance treatment.

The important difference is that when symptoms increase, the patient receives more anti-inflammatory treatment as well as more reliever medicine. This aims to reduce the cycle of worsening symptoms, repeated blue inhaler use, and untreated inflammation.

Useful patient information is available from Asthma + Lung UK on AIR inhalers and MART inhalers.

Does this mean everyone should stop using their blue inhaler?

No. This is the most important point.

The new guidance does not mean that every patient must immediately stop using a blue inhaler. It also does not mean that blue inhalers are “bad” or banned.

For many people, nothing will change straight away. Some patients will remain on their current inhalers. Others may be changed to an AIR or MART plan after review by their GP, asthma nurse or respiratory specialist.

Will some patients have their blue inhaler taken away?

Sometimes, but not always.

If a patient is moved onto an AIR or MART plan, their combination inhaler may become both their preventer and their reliever. In that situation, they may no longer routinely need a separate blue inhaler.

However, some patients may still keep a blue inhaler as backup, and others may continue with separate preventer and reliever inhalers. This depends on the individual patient, their diagnosis, their inhalers, and their asthma action plan.

Not all combination inhalers can be used as relievers. Only specific inhalers containing a fast-acting medicine such as formoterol are suitable for AIR or MART use. Patients should only use inhalers in this way if they have been specifically prescribed and instructed to do so.

Why this is more complicated for aspergillosis patients

People with aspergillosis-related lung disease often have more complex respiratory problems than standard asthma alone.

This may include:

For these patients, breathlessness is not always caused by asthma-type inflammation alone. It may also be related to mucus, infection, bronchiectasis, fungal activity, or structural lung damage.

This means that simply taking more inhaler may not always address the real cause of worsening symptoms.

Steroids: useful but needing balance

Inhaled corticosteroids can be very helpful in asthma and ABPA because they reduce airway inflammation. Good control of inflammation may reduce symptoms, flare-ups and the need for oral steroid courses.

However, steroid exposure also needs careful management in aspergillosis patients. Higher steroid doses may increase the risk of side effects such as oral thrush and, in some situations, may affect the balance between inflammation control and fungal growth.

This does not mean patients should avoid inhaled steroids. It means that treatment should be individualised and reviewed by a clinician who understands the patient’s full lung condition.

What should aspergillosis patients do?

  • Do not stop your blue inhaler suddenly if it has been prescribed for you.
  • Do not change your preventer or steroid inhaler without medical advice.
  • Check your own asthma action plan. Make sure you know which inhaler is for daily prevention and which one is for symptoms.
  • Ask whether your combination inhaler is suitable for AIR or MART use. Do not assume that all combination inhalers can be used this way.
  • Request a review if you are using your reliever inhaler frequently, symptoms are worsening, or you are unsure what to do.

When to seek urgent help

Seek urgent medical help if your breathlessness is severe, your reliever is not helping as expected, you are struggling to speak in full sentences, your lips or fingers look blue, or your symptoms are rapidly worsening.

Follow your personal asthma action plan. If you think you are having an asthma attack, do not delay seeking emergency help.

The key message

The new guidance is not simply about “taking away blue inhalers”. It is about recognising that asthma symptoms often reflect airway inflammation, and that some patients do better when symptom relief and anti-inflammatory treatment are given together.

For people with aspergillosis, the message is especially important: inhaler treatment should be reviewed in the context of the whole lung condition, not changed because of a headline.

If you are unsure about your inhalers, speak to your GP, asthma nurse, respiratory consultant or aspergillosis team.


Further reading


Weekly aspergillosis research update infographic showing diagnostics, treatment challenges, antifungal resistance and patient risk factors

Weekly Aspergillosis Research Update April - May 2026

Search term: aspergillosis
Period covered: late April–early May 2026

Key highlights this week

  • Diagnostics: new evidence for pentraxin-3 and airway galactomannan testing.
  • Treatment: voriconazole dosing may be difficult during ECMO and needs close monitoring.
  • Resistance: azole-resistant Aspergillus fumigatus detected around patient homes in Brazil.
  • Transplant medicine: aspergillosis remains the dominant invasive mould infection after lung transplantation.
  • Future therapies: early laboratory work identifies a possible new antifungal drug target.

1. New diagnostic marker: pentraxin-3 for invasive pulmonary aspergillosis

Sun C et al. Diagnostic value of pentraxin 3 in plasma and bronchoalveolar lavage fluid for invasive pulmonary aspergillosis in non-neutropenic patients: a prospective multicenter clinical study. Emerging Microbes & Infections, 2026.

View on PubMed – PMID: 42054395

This prospective multicentre study looked at pentraxin-3 in blood and bronchoalveolar lavage fluid as a diagnostic marker for invasive pulmonary aspergillosis in patients who are not neutropenic.

Why it matters: diagnosing invasive aspergillosis can be especially difficult in patients outside the classic high-risk groups. This study supports the wider move toward combining tests and biomarkers rather than relying on one result alone.


2. Galactomannan testing in tracheobronchial aspirates after lung transplant

Monforte A et al. Diagnostic value of galactomannan in tracheobronchial aspirate for Aspergillus infection in lung transplant recipients (the GALACTBAS study). Journal of Clinical Microbiology, 2026.

View on PubMed – PMID: 42059612

This study assessed whether galactomannan testing in tracheobronchial aspirates can help diagnose Aspergillus infection in lung transplant recipients.

Why it matters: aspergillosis after lung transplantation often involves the airways. Testing airway samples may support earlier diagnosis and may sometimes be less invasive than deeper lung sampling.


3. Voriconazole levels may vary during ECMO

Yusuff H et al. Time-varying voriconazole clearance during extracorporeal membrane oxygenation. Antimicrobial Agents and Chemotherapy, 2026.

View on PubMed – PMID: 42059809

This paper looked at voriconazole clearance in critically ill patients receiving extracorporeal membrane oxygenation (ECMO).

Why it matters: voriconazole is commonly used to treat invasive aspergillosis, but drug levels can be unpredictable in critical illness. This supports the importance of therapeutic drug monitoring so dosing can be adjusted safely and effectively.


4. Azole-resistant Aspergillus found around patient homes in Brazil

de Barros Rodrigues DK et al. Environmental circulation of Aspergillus fumigatus with reduced susceptibility to agricultural triazole in Brazil: clonal dissemination of potentially resistant genotypes. Mycoses, 2026.

View on PubMed – PMID: 42037564

This study investigated environmental Aspergillus fumigatus around the homes of two patients with suspected aspergillosis caused by resistant isolates.

Why it matters: the findings add to concern that antifungal resistance can arise and circulate in the environment, including through exposure to agricultural triazoles. This is important because azole resistance can make aspergillosis harder to treat.


5. Invasive mould infections after lung transplantation: aspergillosis dominates

Pennington KM et al. Impact of invasive mold infection-coded diagnoses on utilization, costs, and mortality after lung transplantation. Chest, 2026.

View on PubMed – PMID: 42061698

This study assessed invasive mould infection-coded diagnoses after lung transplantation. Aspergillosis was the most common invasive mould infection reported.

Why it matters: lung transplant recipients remain among the highest-risk groups for severe aspergillosis. The study reinforces the need for prevention, early recognition, rapid diagnosis and specialist management.


6. A possible new antifungal target in Aspergillus fumigatus

Storer ISR et al. A protein-protein interaction inhibitor arrests the cell cycle in Aspergillus fumigatus. mBio, 2026.

View on PubMed – PMID: 42053292

This laboratory study explored a compound that interferes with protein-protein interactions and can arrest the cell cycle in Aspergillus fumigatus.

Why it matters: current antifungal options remain limited, and resistance is a growing problem. Early-stage work like this may help identify future antifungal drug classes.


7. Diabetes and fungal infection risk

Kaur H et al. Fungal infections in diabetes mellitus. Indian Journal of Medical Microbiology, 2026.

View on PubMed – PMID: 42061613

This review discusses fungal infections in people with diabetes, including mucormycosis, aspergillosis and cryptococcosis.

Why it matters: diabetes can affect immune function and increase susceptibility to some infections. For patients with existing lung disease, good diabetes management may be one part of reducing overall infection risk.


8. Aspergillosis during cancer immunotherapy

Niravath P et al. A Phase II Study of Docetaxel and Pembrolizumab plus Interleukin 12 Gene Therapy in Nonmetastatic, Anthracycline-Refractory Triple-Negative Breast Cancer (INTEGRAL). Clinical Cancer Research, 2026.

View on PubMed – PMID: 41661218

This cancer therapy study includes a reported case of pulmonary aspergillosis and respiratory failure during treatment.

Why it matters: modern cancer treatments can alter infection risk in complex ways. Aspergillosis should remain on the radar in patients who become unwell during or after intensive cancer therapy.


Other papers noted this week

  • Canakinumab safety pharmacovigilance analysis – relevant to biologic therapy safety and infection monitoring. PMID: 41998856
  • Canine sinonasal radiotherapy study – includes nasal aspergillosis in dogs, but is mainly veterinary/radiotherapy focused. PMID: 42007656
  • Mucormycosis retrospective study – relevant to invasive fungal disease burden but not directly focused on aspergillosis. PMID: 42050055

Overall message

This week’s papers show how aspergillosis research is moving in several important directions at once: better diagnostic markers, more personalised antifungal dosing, growing concern about environmental resistance, and continued recognition of high-risk groups such as transplant recipients, critically ill patients and people with complex immune or metabolic conditions.

For patients, the main message is that aspergillosis is a complex condition and testing or treatment decisions often need specialist interpretation. No single test result tells the whole story; clinicians usually combine symptoms, scans, culture results, biomarkers and risk factors before deciding on diagnosis and treatment.


Infographic summarising weekly aspergillosis research including ABPA biologics, antifungal resistance, occupational exposure and invasive aspergillosis studies (April 2026)

Weekly Aspergillosis Research Update: Week ending 27 April 2026

Highlights this week

  • Occupational aspergillosis: workplace exposure to Aspergillus highlighted in a national study.
  • ABPA and biologics: early evidence for tezepelumab in allergic bronchopulmonary aspergillosis.
  • Mucus plugging: important mechanism in ABPA, bronchiectasis and chronic lung disease.
  • Invasive disease: new analysis of antifungal treatment strategies.
  • Resistance: ongoing global surveillance of antifungal susceptibility.

Occupational non-invasive aspergillosis

A French national multicentre study reviewed occupational cases of non-invasive aspergillosis over more than 20 years.

Why it matters: workplace exposure (dust, compost, damp buildings, waste handling) may contribute to disease in some patients and should be considered in clinical history-taking.

Reference: Michel A et al.

PMID: 42033338

Tezepelumab in allergic bronchopulmonary aspergillosis

A small 4-patient case series explored the use of tezepelumab in allergic bronchopulmonary aspergillosis (ABPA) with severe asthma.

Why it matters: adds to growing interest in biologics for ABPA, particularly where steroid burden is high. Evidence remains early and limited.

Reference: Sanz-Sanjosé B et al.

PMID: 42017435

Mucus plugging in chronic lung disease

A narrative review examined mucus plugging in chronic obstructive lung diseases and bronchiectasis, including ABPA.

Why it matters: mucus plugs can block airways, worsen breathlessness, and contribute to infection risk and scan abnormalities.

Reference: Schou C et al.

PMCID: PMC13103984

Invasive aspergillosis treatment

A systematic review and network meta-analysis compared antifungal treatment regimens for invasive aspergillosis.

Why it matters: invasive aspergillosis remains a high-mortality infection; early diagnosis and optimal antifungal therapy are critical. Triazoles and other antifungals remain central to management. :contentReference[oaicite:0]{index=0}

Reference: Gu Q et al.

PMID: 42012594

Natural killer cells and resistant Aspergillus

A laboratory study demonstrated antifungal activity of human natural killer cells against azole-resistant Aspergillus fumigatus.

Why it matters: improves understanding of immune defence mechanisms and may inform future therapies.

Reference: Namie H et al.

PMID: 42012259

Antifungal susceptibility surveillance

A multicentre Taiwan study examined susceptibility patterns of clinical Aspergillus isolates (2021–2023).

Why it matters: resistance patterns vary geographically, influencing antifungal treatment choices.

Reference: Hsieh M et al.

PMID: 42012212

Invasive aspergillosis in severe viral illness

A study explored invasive pulmonary aspergillosis complicating severe fever with thrombocytopenia syndrome.

Why it matters: reinforces the link between severe illness, immune disruption, and risk of invasive aspergillosis.

Reference: Du Q et al.

PMID: 42032512

Lower-priority or indirect papers

Veterinary study (canine nasal aspergillosis)

Primarily a veterinary oncology study with limited relevance to human disease.

Reference:

PMID: 42007656

Canakinumab pharmacovigilance

Focuses on drug safety rather than aspergillosis.

Reference:

PMID: 41998856

Overall message

This week’s research highlights the wide scope of aspergillosis—from environmental and occupational exposure to allergic disease, invasive infection, antifungal resistance, and immune responses. The most relevant developments for patients remain ABPA biologics, mucus plugging, and antifungal resistance trends.

Patient note

This summary is for general information only and does not replace medical advice. Always discuss treatment decisions with your specialist team.


Diagram showing why aspergillosis is often controlled rather than cured, including differences between ABPA and chronic pulmonary aspergillosis (CPA)

Can Aspergillosis Be Cured? Understanding Treatment, Control, and Long-Term Therapy

Last reviewed: April 2026


Key points

  • Aspergillosis is caused by fungi from the Aspergillus group.
  • Most people breathe in Aspergillus spores regularly without becoming ill.
  • In some people, damaged airways, lung cavities, mucus plugs, or immune responses allow the fungus or fungal material to persist.
  • Antifungal treatment may aim to cure, but in many cases the goal is long-term control.
  • Steroids can reduce harmful inflammation in allergic disease, but they can also reduce the body’s ability to clear fungus.

Table of contents


Overview

It is very common for people diagnosed with aspergillosis to feel worried when they read that others have been taking antifungal medication for months or even years.

This can lead to an understandable question:

“Does treatment actually work, or will I have this forever?”

The answer is more nuanced than a simple yes or no. Different forms of aspergillosis behave differently, and treatment goals vary depending on the condition.

Two of the most common conditions are:

Understanding this difference is key to understanding why treatment may continue for a long time.

If you would like a more detailed explanation of how these conditions are diagnosed and managed, see our guides to chronic pulmonary aspergillosis (CPA) and allergic bronchopulmonary aspergillosis (ABPA).


Why breathing in spores does not usually cause disease

Aspergillus spores are present in the environment, including air, soil, compost, dust, and decaying vegetation. Most people breathe in small numbers of these spores regularly without becoming ill.

In healthy lungs, spores are usually cleared by the immune system and by the normal cleaning mechanisms of the airways.

This means:

  • Exposure to Aspergillus is common
  • Most exposure does not lead to disease
  • Aspergillosis usually develops only when there are additional risk factors, such as lung damage, mucus trapping, or altered immune responses

So it is not accurate to think of most patients as being “constantly reinfected”. A better way to think about it is that some lungs provide conditions where Aspergillus, or fungal material, can persist and continue to cause problems.


Why aspergillosis can be hard to clear

Aspergillosis can be difficult to clear for several reasons. These include the structure of the lungs, the biology of the fungus, limitations of drug penetration, and the way the immune system responds.

1. Damaged lung tissue can provide protected spaces

In CPA, Aspergillus often grows in areas of abnormal lung, such as cavities, scarred tissue, or areas affected by bronchiectasis.

These areas can act as protected spaces where the fungus is harder for the immune system and antifungal medicines to reach.

2. Thick mucus can trap fungus and fungal material

In airway diseases such as asthma, bronchiectasis, and ABPA, thick mucus can trap spores, hyphae, and fungal fragments.

This trapped material can continue to stimulate inflammation even when the fungus is not invading lung tissue.

3. Antifungal medicines may suppress rather than sterilise

Antifungal medications can reduce fungal activity and help prevent progression, but they may not always remove every trace of fungus from damaged lung spaces or mucus-filled airways.

For this reason, success is often measured by:

  • Improved symptoms
  • Stabilised weight and energy
  • Fewer flare-ups
  • Stable or improved scans
  • Prevention of further lung damage

Infection and ABPA: different reasons for persistence

Chronic pulmonary aspergillosis: persistence of infection

In chronic pulmonary aspergillosis, the problem is fungal growth in damaged lung tissue.

  • Lung cavities provide spaces where fungus can grow
  • Drug penetration may be limited
  • The immune system may not fully clear infection

Allergic bronchopulmonary aspergillosis: persistence of reaction

In ABPA, the main issue is an exaggerated immune response.

  • Mucus traps fungal material
  • Small amounts can trigger strong reactions
  • Inflammation leads to more mucus

Do steroids influence this?

Yes. Steroids can be helpful but must be used carefully.

In ABPA, they reduce inflammation but may also reduce fungal clearance.

In chronic infection, steroids can increase the risk of persistence or progression.

Monitoring and drug interactions are important during treatment.


Control vs cure: what is the goal?

For many people, the realistic goal is:

  • Stability rather than eradication
  • Reduced symptoms
  • Prevention of progression

 

Diagram showing why aspergillosis is often controlled rather than cured, including differences between ABPA and chronic pulmonary aspergillosis (CPA)
Aspergillosis is often managed as a long-term condition. This diagram shows why complete cure can be difficult and how treatment focuses on control.

Common antifungal treatments

  • Itraconazole
  • Voriconazole
  • Posaconazole

These treatments are selected based on individual factors and require monitoring.


Why don’t I hear many success stories?

People who improve often post less, while those still struggling are more visible in forums.


When to seek medical advice

  • Uncertainty about treatment
  • Side effects
  • Weight loss
  • Worsening symptoms

Common questions

Can aspergillosis be cured?

Sometimes, but often it is managed long-term.

Are people constantly reinfected?

No. Most people clear spores regularly without issue.

Why is ABPA difficult to treat?

Because of ongoing immune reactions and mucus trapping.


Further reading



Recurrent chest infections not responding to antibiotics infographic showing ABPA and CPA pathways

When ‘chest infections’ don’t respond: when to suspect ABPA or CPA (Clinical perspective)

Patients presenting with recurrent “chest infections” that do not respond to antibiotics are common in primary and secondary care. In a subset of these cases, the underlying cause may not be bacterial, but related to fungal disease or immune-mediated responses to Aspergillus.

This article summarises when to suspect allergic bronchopulmonary aspergillosis (ABPA) or chronic pulmonary aspergillosis (CPA), and how to move from repeated empirical treatment to a more structured diagnostic approach.


Key clinical message

Repeated antibiotic-treated exacerbations with limited response, particularly when symptoms improve with steroids and then relapse, should prompt reconsideration of the diagnosis.


When to suspect ABPA or CPA

Consider aspergillosis-related disease in patients with:

  • Recurrent “chest infections” with poor or inconsistent antibiotic response
  • Steroid-responsive symptoms with relapse on reduction or cessation
  • Persistent or unexplained radiological abnormalities
  • Underlying lung disease:
    • Asthma
    • Bronchiectasis
    • Chronic obstructive pulmonary disease (COPD)
    • Previous tuberculosis or lung damage
  • Raised or previously documented abnormalities in:
    • Total IgE
    • Eosinophils
    • Aspergillus-specific markers (if previously tested)

These features are not diagnostic in isolation but should raise suspicion when seen together.


ABPA vs CPA: clinical distinction

Feature ABPA CPA
Primary mechanism Immune-mediated (allergic) Chronic fungal infection
Typical background Asthma, bronchiectasis Structural lung disease, prior TB, COPD
Steroid response Often marked Variable (may improve symptoms but not disease)
Antibiotic response Limited Limited
Radiology Mucus plugging, bronchiectasis Cavities, fungal balls, fibrosis

Common pitfalls in practice

  • Repeated empirical antibiotics despite poor response
  • Short courses of steroids without a long-term management plan
  • Reliance on chest X-ray alone in persistent or atypical cases
  • Failure to recognise patterns across multiple consultations or admissions

These patterns can lead to prolonged diagnostic delay, which is well described in CPA and ABPA.


Suggested diagnostic approach

1. Reassess the working diagnosis

When standard treatment fails, explicitly reconsider whether the presentation remains consistent with bacterial infection.

2. Imaging

  • Escalate from chest X-ray to CT thorax where appropriate
  • Look for:
    • Cavitation
    • Fungal ball (aspergilloma)
    • Mucus plugging
    • Bronchiectasis

3. Blood tests

  • Total IgE
  • Eosinophil count
  • Aspergillus-specific IgE and IgG (where available)

4. Microbiology / further testing

Depending on context, consider sputum culture, fungal markers, or specialist input.


The steroid–relapse pattern

A common clinical scenario:

Exacerbation → steroids → improvement → relapse

This should raise suspicion of an underlying inflammatory or fungal-driven process rather than recurrent bacterial infection alone.


When to consider referral

Referral to a specialist centre (e.g. National Aspergillosis Centre, Manchester) may be appropriate where:

  • Diagnosis remains uncertain
  • Symptoms are persistent or progressive despite treatment
  • Antifungal therapy is being considered or not tolerated
  • Radiology suggests CPA or complex disease

Referral decisions should be made in the context of overall patient condition, comorbidities, and goals of care.


Why diagnosis is often delayed

  • Overlap with common respiratory conditions
  • Partial response to standard therapies
  • Fragmentation across care settings
  • Limited exposure to aspergillosis in routine practice

Recognising the pattern is often the key step in reducing delay.


Practical takeaways

  • If antibiotics are not working, reconsider the diagnosis
  • If steroids repeatedly improve symptoms, ask why
  • Use CT imaging to clarify persistent abnormalities
  • Aim for a clear, shared management plan

Guidelines and further reading

  • British Thoracic Society. Clinical Statement on Aspergillus-related chronic lung disease
  • ISHAM Working Group. Guidelines for ABPA diagnosis and management
  • Denning DW et al. Chronic pulmonary aspergillosis guidelines

Further professional resources


Aspergillosis.org – Information for healthcare professionals


This article is intended for educational purposes and should be interpreted in the context of individual clinical judgement.


Can overseas patients access specialist centres like NAC? A clear guide for patients and families

Last reviewed: April 2026

Key points

  • Specialist centres such as the National Aspergillosis Centre (NAC) cannot provide individual medical advice directly to patients, especially from overseas.
  • This is due to safety, legal, and clinical responsibility requirements.
  • The correct route is through a local doctor, using a formal referral process.
  • A referral does not guarantee that a patient will be seen.
  • Even when doctors contact specialist centres, there are limits to what can be offered.
  • NAC does not offer private care, although some other centres do.

Table of contents


Why can’t specialist centres respond directly to patients?

It is natural to want to contact a specialist centre directly, especially when dealing with a complex condition such as aspergillosis. However, centres like NAC cannot provide individual medical advice directly to patients.

This is not a matter of choice—it is because they cannot safely or legally do so.

Patient safety

  • Safe medical advice requires full access to medical records, test results, and examination findings
  • Doctors must be able to monitor progress and adjust treatment
  • This cannot be done through messages or emails alone

Legal and regulatory requirements

  • Doctors must follow strict rules set by regulators such as the General Medical Council (GMC) in the UK
  • They cannot take responsibility for a patient without a formal clinical relationship

Responsibility for care

  • Any doctor giving advice must be able to take responsibility for outcomes
  • This requires recognised clinical pathways and follow-up arrangements

In summary: Specialist centres are not refusing help—they cannot provide care outside safe and regulated systems.


The correct way to get help

The safest and most effective way to access specialist expertise is through your local doctor.

Step 1 – See a local specialist

  • Respiratory doctor
  • Infectious disease specialist
  • Internal medicine specialist

Step 2 – Assessment and initial care

  • Your doctor reviews your symptoms and history
  • Tests are arranged where needed
  • Treatment may be started

Step 3 – Referral or specialist advice

This approach ensures your care is coordinated, safe, and based on full clinical information.


What does a referral mean?

A referral is when your doctor formally asks another specialist or centre to review your case or consider seeing you.

This is not just a message—it is a structured clinical process.

What does a referral usually include?

  • Your medical history
  • Details of your symptoms
  • Results of tests (such as scans or laboratory results)
  • Treatments you have already received
  • A clear reason for referral

This allows the specialist centre to understand your situation safely and properly.

What happens next?

After reviewing the referral, the specialist centre may:

  • ✔️ Accept the referral and arrange an appointment
  • ✔️ Provide advice to your doctor without seeing you
  • ✔️ Suggest a more appropriate service
  • ❌ Decline the referral

A referral is like a formal handover between doctors—it does not guarantee an appointment.


Will a referral always be accepted?

Even when your doctor makes a referral, it is important to understand that the referral may not always be accepted.

Why might a referral not be accepted?

Eligibility criteria

  • Specialist centres often have strict criteria for the patients they can see
  • Some services are commissioned only for specific conditions

Geographic and funding rules

  • Access may depend on healthcare system or funding arrangements

Clinical suitability

  • The centre may decide your care can be managed locally
  • They may offer advice instead of accepting the referral

Capacity

  • Specialist centres often manage large numbers of complex patients

What happens if it is not accepted?

  • Your doctor may still receive expert advice
  • You may be directed to another service
  • Your care continues locally

This does not mean you are being refused help.


Why specialist centres may not be able to confirm anything to you

Patients and families sometimes ask a specialist centre whether a referral has been received, reviewed, or accepted.

It is important to understand that the centre may not be able to confirm or discuss this with you directly.

Why is this?

Confidentiality and data protection

  • Medical information is protected by strict confidentiality rules
  • In the UK, this includes laws such as data protection legislation and professional duties of confidentiality
  • Centres must be certain they are communicating with the correct person and through approved channels

Communication is usually between doctors

  • Referrals are handled as clinician-to-clinician communication
  • Responses are normally sent back to the referring doctor, not directly to the patient

No confirmation does not mean no action

  • If you do not receive a reply from the centre, it does not necessarily mean your referral has been ignored
  • Advice or decisions may already have been communicated to your doctor

What should you do?

  • Contact your own doctor for updates
  • Ask whether a referral has been sent and if a response has been received
  • Discuss next steps with your clinical team

Summary

Specialist centres usually communicate with your doctor, not directly with patients. This is to protect your privacy and ensure safe, appropriate communication.


Do personal requests from patients or families help?

Personal requests are completely understandable, but specialist centres cannot provide individual medical advice directly to patients, even in urgent situations.

This is because they cannot safely or legally do so without a doctor involved.

These requests may still help with general information and guidance, but they do not usually lead to diagnosis or treatment advice.


Limits even when doctors are involved

When your doctor contacts a specialist centre, this is the correct route—but there are still limits.

What specialist centres can offer

  • Expert opinion
  • Suggestions for diagnosis
  • Guidance on tests
  • Interpretation of results

What they cannot usually provide

  • Direct patient care
  • Full responsibility for treatment
  • Definitive diagnosis without full assessment

Your local doctor remains responsible for your care.


What about private care?

The National Aspergillosis Centre (NAC) does not offer private care.

  • You cannot arrange to be seen there privately
  • Access is through NHS referral pathways only

Some other specialist centres may offer private consultations. However:

  • A referral and medical records are usually required
  • An in-person assessment is typically needed
  • Private care does not bypass safety or legal requirements

Common myths

  • “I can contact a specialist centre directly for help”
    → Centres cannot provide individual advice directly to patients
  • “If it’s urgent, they will make an exception”
    → The same safety rules apply to all patients
  • “A referral guarantees I will be seen”
    → Referrals are reviewed and may not always be accepted
  • “Private care means I can be seen anywhere”
    → Not all centres offer private care (NAC does not)
  • “A detailed email is enough for diagnosis”
    → Diagnosis requires full clinical assessment

When to seek urgent medical help

If you or someone you care for has any of the following, seek urgent local medical care:

  • Severe breathlessness
  • Chest pain
  • Coughing up blood
  • Confusion or extreme drowsiness
  • High fever that is not improving

Do not delay seeking help while trying to contact overseas specialists.


Summary

Specialist centres such as NAC play an important role in supporting complex conditions like aspergillosis. However, they must work within systems designed to keep patients safe.

The most effective way to access their expertise is through your own doctor, using formal referral pathways and specialist advice where needed.


Author & review information

Prepared for patient education purposes.
Aligned with UK specialist centre practice and patient safety guidance.

References & further reading


AntifungalInteractions.org – A Specialist Resource for Safer Antifungal Treatment

Last reviewed: April 2026

Managing antifungal medications can be complex. Many antifungal drugs interact with other medicines, foods, and even supplements.
To support both patients and healthcare professionals, a dedicated resource is available:
AntifungalInteractions.org.


Key Points

  • A specialist database focused specifically on antifungal drug interactions
  • More detailed and targeted than general resources such as the British National Formulary (BNF)
  • Includes guidance designed for both healthcare professionals and patients
  • Regularly updated (typically several times per month)
  • Maintained by an experienced clinical pharmacist and prescriber
  • Owned and supported by the Fungal Infection Trust

What is AntifungalInteractions.org?

AntifungalInteractions.org is a dedicated online database designed to help users understand how antifungal medications interact with:

  • Other prescribed drugs
  • Over-the-counter medications
  • Herbal supplements
  • Certain foods and drinks

Unlike general drug reference tools, this resource focuses specifically on antifungal medicines, making it particularly useful for conditions such as aspergillosis, where treatment often involves long-term or complex therapy.


Why This Resource Matters

1. Antifungal drugs are complex

Common antifungal medications such as azoles (e.g. itraconazole, voriconazole, posaconazole) are known to interact with many other drugs.
These interactions can:

  • Increase side effects
  • Reduce treatment effectiveness
  • Require dose adjustments or monitoring

2. General resources may not go far enough

Widely used tools like the British National Formulary (BNF) are essential, but they are designed for broad use across all medicines.
AntifungalInteractions.org provides:

  • More detailed interaction explanations
  • Practical interpretation of risk
  • Condition-specific relevance

3. It supports informed discussions

The database is not a replacement for clinical advice, but it can help patients and clinicians:

  • Prepare for consultations
  • Understand potential risks
  • Ask more informed questions

Who Maintains the Database?

AntifungalInteractions.org is maintained by:

Saarah Niazi-Ali
MPharm, PG Cert (General Pharmacy Practice), PG Dip (Advanced Clinical Pharmacy Practice),
Independent Pharmacist Prescriber, Non-Medical Prescribing (Level 7), Final Medical Signatory

The database is updated frequently—typically 3–4 times per month, often on a weekly basis—ensuring that information remains current and clinically relevant.


Governance and Ownership

The resource is owned and supported by the Fungal Infection Trust, a UK-based organisation dedicated to improving the understanding, diagnosis, and treatment of fungal diseases.

This ensures that the database:

  • Remains focused on patient benefit
  • Is aligned with specialist fungal disease care
  • Supports both clinical practice and patient education

Who Is It For?

Patients and carers

  • To better understand their medications
  • To check for potential interactions
  • To support conversations with their clinical team

Healthcare professionals

  • Infectious disease specialists
  • Respiratory clinicians
  • Pharmacists
  • GPs managing complex patients

It is particularly valuable for clinicians managing conditions such as:

  • Chronic pulmonary aspergillosis (CPA)
  • Allergic bronchopulmonary aspergillosis (ABPA)
  • Other fungal infections requiring long-term antifungal therapy

How Does It Compare to Other Resources?

Feature AntifungalInteractions.org General Drug References (e.g. BNF)
Focus Antifungal-specific All medicines
Level of detail High (specialist) Moderate (broad coverage)
Patient-friendly explanations Yes Limited
Update frequency Frequent (monthly/weekly) Regular but broader scope

Important Notes for Patients

While this database is a valuable resource, it should be used appropriately:

  • Do not stop or change medication based on what you read
  • Always discuss concerns with your doctor, pharmacist, or specialist team
  • Use the information to support—not replace—medical advice

When to Seek Medical Advice

Contact your healthcare provider if you:

  • Start a new medication while on antifungal treatment
  • Experience new or worsening side effects
  • Are unsure whether a supplement or food is safe
  • Have been advised of a potential interaction

Summary

AntifungalInteractions.org is a highly valuable, specialist resource that fills an important gap in antifungal care.
Its combination of:

  • Expert clinical oversight
  • Frequent updates
  • Patient-accessible explanations
  • Specialist focus

makes it an important tool for both patients and healthcare professionals managing fungal disease.


Further Reading


Author & Review

Prepared for Aspergillosis patient and healthcare education.
Content aligned with UK specialist practice and reviewed for clarity and safety.


Help shape the future of aspergillosis care across Uk & Europe

Many people living with aspergillosis, and many carers, reach a point where they ask:

“Can patients do more than just cope with this condition?”

The answer is yes.

The European Lung Foundation (ELF)
and its
Aspergillosis Patient Advisory Group (PAG)
give patients and carers a chance to contribute to something bigger: better awareness, better information, better research, and better care.

What is ELF?

ELF is a Europe-wide organisation that brings patients, carers, healthcare professionals and researchers together to improve lung health information, treatment and care.

One of ELF’s strongest advantages is that it works across Europe, not just in one country. It also makes key information available in several languages, helping more people access reliable information about lung conditions, including aspergillosis.

You can read ELF’s patient information on aspergillosis here:
Aspergillosis – European Lung Foundation.

What is the Aspergillosis Patient Advisory Group?

The Aspergillosis PAG is part of ELF’s wider network of
Patient Advisory Groups.
These groups bring together people with experience of specific lung conditions, or experience as carers, so that patient views can help improve treatment and healthcare.

The Aspergillosis PAG works to raise awareness of aspergillosis and improve diagnosis, treatment and care. It also works alongside healthcare professionals and researchers involved in the Chronic Pulmonary Aspergillosis Network (CPAnet), helping identify research priorities and information gaps for both patients and professionals.

Why does this matter?

Aspergillosis is still not well understood in many places. Diagnosis can be delayed, information can be hard to find, and patients often feel that few people truly understand what living with the condition is like.

By involving patients and carers directly, ELF helps ensure that real-life experience is not left out of the conversation. This can influence education, awareness work, research priorities and wider discussions about care across Europe.

What is in it for the patient or carer?

This is an important question, because volunteering your time and energy is a big ask, especially when you are already managing illness, fatigue, appointments, uncertainty or caring responsibilities.

So it is only fair to be clear and honest about what people may gain from taking part.

1. A chance to make your experience count

Many people with aspergillosis have learned difficult lessons the hard way. Getting involved gives you a chance to turn that experience into something useful — helping improve information, shape priorities and make life a little easier for future patients.

2. Better understanding and confidence

Being involved can help you better understand how research, awareness work and patient representation operate. Some people find that this gives them more confidence when speaking about their condition and navigating their own care.

3. Connection beyond your local area

Because ELF is Europe-wide, patients are not limited to the perspective of one hospital, one region or one country. For people living with a relatively uncommon condition, that wider connection can feel valuable and reassuring.

4. The opportunity to be heard

Many patients are used to feeling overlooked. PAGs are designed so that patient and carer perspectives are actively included in projects and discussions, rather than being an afterthought.

5. A sense of purpose

Some people find that involvement helps them move from simply living with a difficult condition to doing something constructive with that experience. It will not suit everyone, but for some it can be meaningful.

6. Support and training

ELF says it provides support, guidance and training to help people share their perspective and get involved in projects. It also encourages interested patients and carers to use its free online European Patient Ambassador Programme (EPAP), which introduces the skills and knowledge needed to represent yourself and others effectively.

What it is not

It is also important to be realistic.

  • It is not medical care.
  • It does not replace your doctor, nurse or specialist team.
  • It is not a route to faster treatment.
  • It is not a paid role.

ELF states that PAG involvement is voluntary and that it is unable to pay for people’s time.

Who can join?

ELF says most PAGs are open to new members from European countries. In general, people are invited to get involved if they are over 18, have experience as a patient or carer, live in a European country, can communicate in English, are interested in improving healthcare and treatment across Europe, and are willing to share their perspective.

That said, this should not feel like an all-or-nothing commitment. Not everyone can give a lot of time, and health can change. Even modest involvement can still be worthwhile.

Why mention this to our groups?

Many people in aspergillosis support communities have exactly the kind of insight that is valuable here: the reality of diagnosis, treatment, daily management, side effects, uncertainty, isolation, and learning how to cope.

Those experiences matter. They can help improve what is researched, what is explained, and how future patients are supported.

Interested?

You can explore more here:

You do not need to be an expert. You do not need to be highly confident. You do not need to commit to everything.

But if you have lived with aspergillosis, or cared for someone who has, your experience may be more valuable than you think.


In short: this is a voluntary opportunity to help improve understanding, research and care for aspergillosis across Europe, while connecting with a wider patient community and making sure lived experience is heard.


Why do doctors ask me to repeat my history — and sometimes not read my summary?

Last reviewed: 9 April 2026

Many patients, especially those with long-term or complex health problems, say the same thing: “Why do I always have to repeat everything?” Some also say that even when they bring a short written summary, it is put to one side and does not seem to be read straight away.

This can feel frustrating, tiring, and dismissive. In most cases, though, it is not because the doctor does not care. It is usually because of how medical appointments are structured, how clinicians are trained, and the time pressures built into the healthcare system.

This article explains what may be happening, why doctors often work this way, and what can sometimes help patients get more out of appointments.

Key points

  • Doctors are usually not ignoring you or your efforts.
  • They are trained to hear the story directly from the patient for safety and accuracy.
  • Medical notes can be long, incomplete, hard to access quickly, or spread across different systems.
  • A written summary can still be helpful, but it may work best as a support tool rather than a replacement for discussion.
  • The system is often particularly difficult for people with complex, long-term conditions.

Contents

Why do doctors ask patients to repeat information?

Many patients assume that if something is already in the notes, the doctor should simply read it and move on. In practice, clinicians are usually taught not to rely only on previous notes. They are expected to take a current history directly from the patient wherever possible.

1. They need a fresh history

Symptoms can change. A note written last week, last month, or even earlier the same day may no longer fully reflect what is happening now. A doctor needs to understand the present situation, not just the recorded one.

This matters because:

  • new symptoms may have appeared
  • older symptoms may have improved or worsened
  • important details may have been left out of earlier notes
  • previous notes can sometimes contain misunderstandings or errors

2. Hearing the story directly is part of diagnosis

Doctors do not just collect facts. They also listen to how symptoms are described, what concerns the patient most, what order things happened in, and whether there are any clues that do not fit the previous record.

For example, hearing a patient say “this is much worse than usual” or “the pain has changed completely” may matter just as much as what is already written down.

3. Each clinician is responsible for their own decisions

Every doctor is professionally responsible for the decisions they make in that consultation. Because of that, they usually need to confirm the key information for themselves rather than relying entirely on another person’s notes or summary.

4. Notes are not always as clear or complete as patients imagine

Patients often assume the notes tell the whole story. Sometimes they do not. They may be brief, scattered across different entries, missing key context, or written in a way that does not quickly explain the current problem.

Why might a written summary be set aside?

Patients who have made the effort to prepare a summary can feel especially upset when a doctor places it to one side. It may look like the document is being ignored. Often, however, the doctor is following a routine approach to consultation rather than rejecting the information.

1. Many consultations follow a familiar structure

Doctors are often trained to work in a rough sequence:

  1. listen to the patient’s account
  2. ask follow-up questions
  3. clarify the current concern
  4. review supporting information and records
  5. decide what to do next

So a written summary handed over at the start may be used later, not immediately.

2. They may not want the written summary to shape their thinking too early

Clinicians are often cautious about being overly influenced by somebody else’s wording before they have heard the patient directly. This is part of clinical reasoning and risk management. They may want to form their own understanding first, then compare it with the summary.

3. Reading while listening can be difficult

In a short appointment, a doctor may feel they cannot properly read a document, listen closely, ask questions, and maintain eye contact all at the same time. They may therefore choose to focus first on the conversation.

4. Some summaries are not easy to use quickly

Even a well-meant summary may be hard to absorb if it is too long, too detailed, or does not make the current issue obvious straight away. Doctors are often trying to answer one urgent question first:

What is the main problem today?

If that is not immediately clear from the page, they may return to direct questioning.

What are doctors trying to achieve?

From a patient’s point of view, repeating information can feel inefficient and unnecessary. From a clinician’s point of view, the consultation is often trying to achieve several things at once:

  • Accuracy: understanding what is happening now, not just what happened before
  • Safety: checking for changes, gaps, or warning signs
  • Clarity: identifying the most important issue for that appointment
  • Responsibility: making decisions based on information they have personally checked

That does not make the experience any less frustrating for patients, but it can help explain the behaviour.

Why is this harder for people with long-term conditions?

This problem is often worse for people who have:

  • complex diagnoses
  • multiple health conditions
  • long medical histories
  • many medications
  • appointments with different teams or hospitals

If you live with a chronic condition, you may have repeated the same history many times. You may also already be tired, breathless, in pain, stressed, or worried. In that situation, being asked again to explain everything can feel overwhelming.

This is a real systems problem. It is not a sign that you are failing to explain yourself properly, and it is not unreasonable to find it difficult.

What can help in appointments?

There is no perfect solution, but some approaches can make appointments easier and increase the chance that useful information is taken in.

Start with the main issue today

A helpful opening sentence can be:

“The main issue today is…”

This quickly gives the doctor a focus and may reduce the need to retell everything in full.

Keep written summaries short

A one-page summary is usually easier to use than a longer document. It can include:

  • main diagnoses
  • current medications
  • important recent events
  • relevant allergies or major problems
  • today’s main concern at the top

Offer the summary rather than relying on it

Instead of assuming it will be read immediately, it may help to say:

“I have brought a short summary in case it is useful.”

or:

“Would it help if I gave you a one-page summary of my background?”

This fits better with how many consultations flow.

Use the summary as a support tool

A written summary often works best as:

  • a memory aid for the patient
  • a quick reference for the doctor
  • a back-up in case important facts are missed

It may be less effective if used as a substitute for the whole conversation.

Say when repetition is difficult

If repeating your history is hard because of pain, fatigue, breathlessness, stress, memory problems, or the complexity of your condition, it is reasonable to say so politely.

“I’m happy to summarise, but I do find repeating the full history difficult.”

That can help the doctor understand the burden on you.

Common questions

Are doctors not reading my notes at all?

Sometimes they have read some of them, but not everything. Sometimes they have skimmed the record for key issues. Sometimes the most relevant information is hard to find quickly. The fact that they ask questions does not always mean they have read nothing.

Why do they not just read my summary instead of asking me?

Because they are usually expected to hear the current story directly, check the important facts for themselves, and understand what matters most right now.

Is there any point bringing a written summary?

Yes. A good summary can still be very helpful. It may save time, improve accuracy, and make it easier to communicate complex information. It is just not always used in the way patients expect.

Does putting my summary to one side mean it has been ignored?

Not necessarily. It may be read later in the appointment, after the consultation, or used as a reference rather than read word for word in front of you.

When to seek further support

You may want more support if:

  • you repeatedly feel that important information is not being understood
  • your condition is complex and hard to explain in a short appointment
  • you feel too unwell or distressed to repeat your history each time
  • you think communication problems are affecting your care

Possible options include:

  • asking whether a clinic letter or care plan summary can be used
  • bringing a relative, friend, or advocate to appointments
  • keeping a short up-to-date medical summary with you
  • asking whether the main issue for that appointment can be agreed early on

Final thought

It can be upsetting to feel that your effort has been overlooked or that you are being asked to say the same things again and again. Usually, though, what you are seeing is not indifference but the way modern consultations are structured around safety, time pressure, and direct assessment.

Your summary is still worth bringing. The most useful expectation is often not that it will replace the conversation, but that it may support it.

Important note

This article is general educational information. It is not medical advice and cannot explain every individual consultation or healthcare setting.

Author and review information

Prepared as general patient information to help explain common experiences in healthcare appointments.